ZIOPHARM Presents Updated Results from Phase 1 Ad-RTS-IL-12 Study in Advanced Melanoma at ASCO

ZIOPHARM Oncology, Inc. ZIOP today announced updated results from the Phase 1 study in advanced melanoma using Ad-RTS-IL-12, a novel DNA-based therapeutic candidate. Findings were presented in a poster presentation at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting being held May 31 – June 4, 2013 at McCormick Place in Chicago, IL. A presentation of the poster, titled "A phase I open-label study of Αd-RTS-hIL-12, an adenoviral vector engineered to express hIL-12 under the control of an oral activator ligand, in subjects with unresectable stage III/IV melanoma," was delivered by Gerald P. Linette, MD, PhD, Associate Professor, Medicine and Neurosurgery, Division of Oncology, at the Washington University School of Medicine. For the study, Ad-RTS-IL-12, an adenoviral vector engineered to express IL-12 utilizing the RheoSwitch Therapeutic System® (RTS®) technology, was injected intratumorally in patients with advanced melanoma (n=14). Expression of IL-12 was controlled through the administration of an oral activator ligand (INXN‑1001), which was administered in four ascending dose cohorts. The Company previously reported that compelling clinical activity was observed in five of seven (71 percent) patients dosed at the two highest dose levels (Nemunaitis et al. ASGCT 2013). The study further See full press release